



TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

YB90004Rb01

Angiotensin I Converting Enzyme (ACE)

Organism: *Oryctolagus cuniculus* (Rabbit)

*Instruction manual*

FOR IN VITRO USE AND RESEARCH USE ONLY

NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES

4th Edition (Revised in February, 2012)

## [ DESCRIPTION ]

**Protein Names:** Angiotensin I Converting Enzyme

**Synonyms:** ACE, CD143

**Species:** Rabbit

**Size:** 100 µg

**Source:** *Escherichia coli*-derived

**Subcellular Location:** Angiotensin-converting enzyme, soluble form: Secreted.  
Cell membrane; Single-pass type I membrane protein.

## [ PROPERTIES ]

**Residues:** Tyr498~Asn715 (Accession # P12822), with N-terminal His-Tag.

**Grade & Purity:** >97%, 26.6 kDa as determined by SDS-PAGE reducing conditions.

**Formulation:** Supplied as liquid form in Phosphate buffered saline(PBS), pH 7.4.

**Endotoxin Level:** <1.0 EU per 1 µg (determined by the LAL method).

**Applications:** SDS-PAGE; WB; ELISA; IP.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted Molecular Mass:** 26.6 kDa

**Predicted isoelectric point:** 5.4

## [ PREPARATION ]

Reconstitute in sterile PBS, pH7.2-pH7.4.



TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

## [ STORAGE AND STABILITY ]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months .

**Stability Test:** The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

## [ SEQUENCES ]

The target protein is fused with N-terminal His-tag, its sequence is listed below.

YLR TKYQGICPPV VRNETHFDAG AKFHIPSVTP YIRYFVSFVL QQFHHQALCM EAGHQGPLHQ CDIIYQSTRAG

AKLRAVLQAG CSRPWQEVK DMVASDALDA QPLLDYFQPV TQWLQEQNER NGEVLGWPEY QWRPPLPNY

PEGIDLVTDE AEASRFVEEY DRSFQAVWNE YAEANWNYNT NITTEASKIL LQKNMQIANH TLTYGNWARR FDVSN

## [ REFERENCES ]

1. Turner AJ., *et al.* (2002) *Can. J. Physiol. Pharmacol.* 80 (4): 346 - 53.
2. Turner AJ., *et al.* (2004) *Trends Pharmacol. Sci.* 25 (6): 291 - 4.
3. Katovich MJ., *et al.* (2005) *Exp. Physiol.* 90 (3): 299 - 305.
4. Ferrario CM., *et al.* (2006) *Am. J. Physiol. Heart Circ. Physiol.* 289 (6): H2281 - 90.
5. Jia HP., *et al.* (2006) *Adv. Exp. Med. Biol.. Advances in Experimental Medicine and Biology* 581: 479 - 84.